Other Clinical Trial - A Clinical Trial of Apatinib Plus Docetaxel in

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05927857` - Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .	Phase 1/Phase 2
Completed	`NCT02539225` - A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2
Active, not recruiting	`NCT03641313` - Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	Phase 2
Recruiting	`NCT03990103` - S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites	Phase 2
Recruiting	`NCT04248452` - Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body	Phase 3
Recruiting	`NCT06324357` - Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread	Phase 1/Phase 2
Recruiting	`NCT04781686` - Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer	Phase 2
Not yet recruiting	`NCT05342389` - Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer	Phase 2
Recruiting	`NCT05269381` - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04660760` - Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	Phase 2
Active, not recruiting	`NCT05555251` - BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04840264` - Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction	Phase 2
Recruiting	`NCT06203600` - Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	Phase 2/Phase 3
Recruiting	`NCT05677490` - mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma	Phase 3
Completed	`NCT02391038` - MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C	Phase 1/Phase 2
Completed	`NCT02314117` - A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer	Phase 3
Recruiting	`NCT05041153` - Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	Early Phase 1
Recruiting	`NCT04007744` - Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT06251973` - A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer	Phase 2
Active, not recruiting	`NCT04220827` - Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer	Phase 1

NCT number	NCT03071042
Study type	Interventional
Source	Sir Run Run Shaw Hospital
Contact	Hongming Pan, MD
Phone	+86-13605716662
Status	Recruiting
Phase	Phase 1
Start date	October 2015
Completion date	June 2018

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms